{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:28:33Z","timestamp":1760059713838,"version":"build-2065373602"},"reference-count":42,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Immune checkpoint inhibitor diabetes mellitus (ICI-DM) is an emerging phenomenon in the adult oncology population, with an increased incidence reflecting the increased use of immunotherapy; however, risk factors for ICI-DM have not been fully identified. The aim of this integrated literature review was to synthesize the published literature on ICI-DM and the factors associated with an increased risk for its development. The review was guided by Sanieszko\u2019s Epidemiology Triad theoretical framework. We conducted a literature search using the Cumulative Index to Nursing and Allied Health Literature, Web of Science, and PubMed databases. The analysis included 2030 studies that met the search criteria, 23 of which were peer-reviewed articles that met the inclusion criteria. The results demonstrated a positive relationship between older age, medical history of diabetes, the presence of susceptible alleles, and exposure to immunotherapy, with an increased risk for ICI-DM. Future studies should include larger samples, more diverse populations, and a broad range of institutions to confirm the risk factors associated with ICI-DM.<\/jats:p>","DOI":"10.3390\/life15071063","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T06:01:33Z","timestamp":1751522493000},"page":"1063","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk Factors Associated with the Development of Immune-Checkpoint Inhibitor Diabetes Mellitus: An Integrative Review"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1519-1658","authenticated-orcid":false,"given":"Vivian","family":"Crowder","sequence":"first","affiliation":[{"name":"Health Science Center, Cizik School of Nursing, University of Texas, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9755-3482","authenticated-orcid":false,"given":"Veronica","family":"Brady","sequence":"additional","affiliation":[{"name":"Health Science Center, Cizik School of Nursing, University of Texas, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2024, August 31). Diabetes. World Health Organization Web Site. Updated 2023. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/diabetes."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Zorena, K., Michalska, M., Kurpas, M., Jaskulak, M., Murawska, A., and Rostami, S. (2022). Environmental Factors and the Risk of Developing Type 1 Diabetes\u2014Old Disease and New Data. Biology, 11.","DOI":"10.3390\/biology11040608"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.immuni.2010.03.018","article-title":"Prediction and Pathogenesis in Type 1 Diabetes","volume":"32","author":"Ziegler","year":"2011","journal-title":"Immunity"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"757","DOI":"10.4093\/dmj.2023.0072","article-title":"Immune-Checkpoint Inhibitors-Induced Type 1 Diabetes Mellitus: From Its Molecular Mechanisms to Clinical Practice","volume":"47","author":"Cho","year":"2023","journal-title":"Diabetes Metab. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1530\/EJE-19-0291","article-title":"Immune checkpoint inhibitors and type 1 diabetes mellitus: A case report and systematic review","volume":"181","author":"Pen","year":"2019","journal-title":"Eur. J. Endocrinol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.2337\/dc21-2213","article-title":"Immune Checkpoint Inhibitors and Risk of Type 1 Diabetes","volume":"45","author":"Chen","year":"2022","journal-title":"Diabetes Care"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.31557\/APJCP.2020.21.6.1697","article-title":"Predictors of the Onset of Type 1 Diabetes Obtained from Real-World Data Analysis in Cancer Patients Treated with Immune Checkpoint Inhibitors","volume":"21","author":"Takada","year":"2020","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Wu, L., Tsang, V.H.M., Sasson, S.C., Menzies, A.M., Carlino, M.S., Brown, D.A., Clifton-Bligh, R., and Gunton, J.E. (2021). Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.764138"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ando.2023.03.012","article-title":"Diabetes Induced by Immune Checkpoint Inhibitors (ICIs)","volume":"84","year":"2023","journal-title":"Ann. D\u2019endocrinologie"},{"key":"ref_10","first-page":"1","article-title":"Patient perspectives on quality of life with uncontrolled type 1 diabetes mellitus: A systematic review and qualitative meta-synthesis","volume":"15","author":"Vanstone","year":"2015","journal-title":"Ont. Health Technol. Assess. Ser."},{"key":"ref_11","unstructured":"American Diabetes Association (2024, September 12). New American Diabetes Association Report Finds Annual Costs of Diabetes to be $412.9 Billion. 1 November 2023. Available online: https:\/\/diabetes.org\/newsroom\/press-releases\/new-american-diabetes-association-report-finds-annual-costs-diabetes-be."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"109053","DOI":"10.1016\/j.intimp.2022.109053","article-title":"Type 1 diabetes with immune checkpoint inhibitors: A systematic analysis of clinical trials and a pharmacovigilance study of postmarketing data","volume":"110","author":"Zhu","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jamaoncol.2024.3104","article-title":"Identification of Immune Checkpoint Inhibitor\u2013Induced Diabetes","volume":"10","author":"Shank","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1095-8649.1974.tb04537.x","article-title":"The effects of environmental stress on outbreaks of infectious diseases of fishes","volume":"6","author":"Snieszko","year":"1974","journal-title":"J. Fish Biol."},{"key":"ref_15","first-page":"22","article-title":"Principles of infectious diseases: Transmission, diagnosis, prevention, and control","volume":"22-39","author":"Hochberg","year":"2017","journal-title":"Int. Encycl. Public Health"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1210\/clinem\/dgad685","article-title":"Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus Is Characterized by C-peptide Loss and Pancreatic Atrophy","volume":"109","author":"Wu","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_17","unstructured":"Critical Appraisal Skills Programme (2024, September 27). CASP Checklist: CASP Cohort Study Checklist. Web Site. Updated 2023. Available online: https:\/\/casp-uk.net\/casp-tools-checklists\/."},{"key":"ref_18","unstructured":"Critical Appraisal Skills Programme (2024, September 27). CASP Checklist: CASP Qualitative Studies Checklist. Web Site. Updated 2023. Available online: https:\/\/casp-uk.net\/casp-tools-checklists\/qualitative-studies-checklist\/."},{"key":"ref_19","unstructured":"Critical Appraisal Skills Programme (2024, September 27). CASP Checklist: CASP Systematic Review Checklist. Web Site. Updated 2023. Available online: https:\/\/casp-uk.net\/casp-tools-checklists\/."},{"key":"ref_20","unstructured":"Critical Appraisal Skills Programme (2024, September 27). CASP Checklist: Systematic Reviews with Meta-Analysis of Observational Studies. Web Site. Updated 2023., Available online: https:\/\/casp-uk.net\/casp-tools-checklists\/systematic-review-checklist\/."},{"key":"ref_21","unstructured":"Grima, L., and Hammerbeck, U. Quality appraisal results using the Critical Appraisal Skills Programme Cohort Studies checklist. Zenodo."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Basak, E.A., De Joode, K., Uyl, T.J.J., van der Wal, R., Schreurs, M.W., Berg, S.A.v.D., Hoop, E.O.-D., van der Leest, C.H., Chaker, L., and Feelders, R.A. (2022). The course of C-peptide levels in patients developing diabetes during anti-PD-1 therapy. Biomed. Pharmacother., 156.","DOI":"10.1016\/j.biopha.2022.113839"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"155311","DOI":"10.1016\/j.metabol.2022.155311","article-title":"Increased risk of incident diabetes after therapy with immune checkpoint inhibitor compared with conventional chemotherapy: A longitudinal trajectory analysis using a tertiary care hospital database","volume":"138","author":"Lee","year":"2022","journal-title":"Metabolism"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2337\/db22-0557","article-title":"Inflammatory Cell Infiltration into Islets Without PD-L1 Expression Is Associated with the Development of Immune Checkpoint Inhibitor\u2013Related Type 1 Diabetes in Genetically Susceptible Patients","volume":"72","author":"Kawata","year":"2023","journal-title":"Diabetes"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Inaba, H., Morita, S., Kosugi, D., Asai, Y., Kaido, Y., Ito, S., Hirobata, T., Inoue, G., Yamamoto, Y., and Jinnin, M. (2023). Amino acid polymorphisms in human histocompatibility leukocyte antigen class II and proinsulin epitope have impacts on type 1 diabetes mellitus induced by immune-checkpoint inhibitors. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1165004"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3803\/EnM.2021.1282","article-title":"Human Leukocyte Antigens and Biomarkers in Type 1 Diabetes Mellitus Induced by Immune-Checkpoint Inhibitors","volume":"37","author":"Inaba","year":"2022","journal-title":"Endocrinol. Metab."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"8144","DOI":"10.1002\/cam4.5616","article-title":"Risk of diabetes mellitus among users of immune checkpoint inhibitors: A population-based cohort study","volume":"12","author":"Chan","year":"2023","journal-title":"Cancer Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral Damage: Insulin-Dependent Diabetes Induced with Checkpoint Inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jemermed.2021.02.020","article-title":"Emergency Presentations of Immune Checkpoint Inhibitor-Related Endocrinopathies","volume":"61","author":"Knight","year":"2021","journal-title":"J. Emerg. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00592-018-1234-8","article-title":"Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: Description of pancreatic endocrine and exocrine phenotype","volume":"56","author":"Marchand","year":"2018","journal-title":"Acta Diabetol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/ejendo\/lvae081","article-title":"HLA investigation in ICI-induced T1D and isolated ACTH deficiency including meta-analysis","volume":"191","author":"Ono","year":"2024","journal-title":"Eur. J. Endocrinol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Muniz, T.P., Araujo, D.V., Savage, K.J., Cheng, T., Saha, M., Song, X., Gill, S., Monzon, J.G., Grenier, D., and Genta, S. (2021). CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes Mellitus. Cancers, 14.","DOI":"10.3390\/cancers14010089"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Iwamoto, Y., Kimura, T., Iwamoto, H., Sanada, J., Fushimi, Y., Katakura, Y., Tatsumi, F., Shimoda, M., Nakanishi, S., and Mune, T. (2023). Incidence of endocrine-related immune-related adverse events in Japanese subjects with various types of cancer. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1079074"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.2337\/dc23-1964","article-title":"Routine Blood Glucose Monitoring Does Not Predict Onset of Immune Checkpoint Inhibitor\u2013Induced Type 1 Diabetes","volume":"47","author":"Akturk","year":"2024","journal-title":"Diabetes Care"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.2337\/dc20-0609","article-title":"Immune Checkpoint Inhibitor\u2013Associated Diabetes: A Single-Institution Experience","volume":"43","author":"Byun","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2217\/imt-2021-0316","article-title":"Clinical Outcomes of Immune Checkpoint Inhibitor Diabetes Mellitus at a Comprehensive Cancer Center","volume":"15","author":"Jeun","year":"2023","journal-title":"Immunotherapy"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"108633","DOI":"10.1016\/j.diabres.2020.108633","article-title":"Characterization of hyperglycemia in patients receiving immune checkpoint inhibitors: Beyond autoimmune insulin-dependent diabetes","volume":"172","author":"Leiter","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"110776","DOI":"10.1016\/j.diabres.2023.110776","article-title":"Incidence of diabetes mellitus in patients treated with immune checkpoint inhibitors (ICI) therapy\u2014A comprehensive cancer center experience","volume":"202","author":"Zhang","year":"2023","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Liu, Y., Liu, H., Zhao, S., Chen, K., and Jin, P. (2023). Clinical and HLA genotype analysis of immune checkpoint inhibitor-associated diabetes mellitus: A single-center case series from China. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1164120"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e00505","DOI":"10.1002\/edm2.505","article-title":"Immune Checkpoint Inhibitors-Induced Endocrinopathies: Assessment, Management and Monitoring in a Comprehensive Cancer Centre","volume":"7","author":"Elshafie","year":"2024","journal-title":"Endocrinol. Diabetes Metab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e000591","DOI":"10.1136\/bmjdrc-2018-000591","article-title":"Immune checkpoint inhibitors: An emerging cause of insulin-dependent diabetes","volume":"7","author":"Kotwal","year":"2019","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5499","DOI":"10.1210\/jc.2019-00423","article-title":"Checkpoint Inhibitor\u2013Associated Autoimmune Diabetes Is Distinct from Type 1 Diabetes","volume":"104","author":"Tsang","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/7\/1063\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:03:44Z","timestamp":1760033024000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/7\/1063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":42,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["life15071063"],"URL":"https:\/\/doi.org\/10.3390\/life15071063","relation":{},"ISSN":["2075-1729"],"issn-type":[{"type":"electronic","value":"2075-1729"}],"subject":[],"published":{"date-parts":[[2025,7,3]]}}}